Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 22 | 2024 | 331 | 9.390 |
Why?
|
| Neonatal Screening | 5 | 2023 | 187 | 1.340 |
Why?
|
| Spleen | 3 | 2024 | 281 | 1.140 |
Why?
|
| Fever | 2 | 2020 | 297 | 0.960 |
Why?
|
| Recombinases | 2 | 2024 | 22 | 0.950 |
Why?
|
| Delphi Technique | 1 | 2024 | 210 | 0.800 |
Why?
|
| Pneumococcal Vaccines | 1 | 2024 | 169 | 0.790 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 79 | 0.790 |
Why?
|
| Splenomegaly | 2 | 2024 | 33 | 0.770 |
Why?
|
| Anesthesia, Conduction | 1 | 2022 | 20 | 0.760 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2024 | 193 | 0.740 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 20 | 0.740 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 129 | 0.690 |
Why?
|
| Malaria | 2 | 2020 | 88 | 0.680 |
Why?
|
| Hemoglobinopathies | 2 | 2023 | 16 | 0.680 |
Why?
|
| Ketamine | 1 | 2023 | 210 | 0.660 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 509 | 0.660 |
Why?
|
| Antimalarials | 2 | 2020 | 40 | 0.650 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2019 | 8 | 0.650 |
Why?
|
| Splenectomy | 1 | 2019 | 62 | 0.620 |
Why?
|
| Laboratories | 1 | 2019 | 81 | 0.610 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 503 | 0.600 |
Why?
|
| Stroke | 2 | 2023 | 982 | 0.580 |
Why?
|
| Developing Countries | 1 | 2020 | 271 | 0.580 |
Why?
|
| Sickle Cell Trait | 2 | 2015 | 11 | 0.540 |
Why?
|
| GATA2 Transcription Factor | 1 | 2016 | 39 | 0.510 |
Why?
|
| Plasmodium yoelii | 1 | 2015 | 2 | 0.500 |
Why?
|
| Plasmodium knowlesi | 1 | 2015 | 2 | 0.500 |
Why?
|
| Trophozoites | 1 | 2015 | 5 | 0.500 |
Why?
|
| Thalassemia | 1 | 2015 | 11 | 0.480 |
Why?
|
| Acetamides | 1 | 2015 | 47 | 0.480 |
Why?
|
| Humans | 32 | 2025 | 125110 | 0.480 |
Why?
|
| Plasmodium falciparum | 1 | 2015 | 67 | 0.480 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 129 | 0.470 |
Why?
|
| Haploinsufficiency | 1 | 2016 | 258 | 0.460 |
Why?
|
| Caregivers | 1 | 2019 | 540 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1097 | 0.450 |
Why?
|
| Child | 13 | 2024 | 24609 | 0.440 |
Why?
|
| Neutropenia | 1 | 2015 | 196 | 0.430 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 225 | 0.430 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2024 | 65 | 0.400 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 377 | 0.400 |
Why?
|
| Pain | 3 | 2023 | 447 | 0.380 |
Why?
|
| Infant, Newborn | 8 | 2023 | 8275 | 0.370 |
Why?
|
| Child, Preschool | 6 | 2024 | 14151 | 0.320 |
Why?
|
| Quality Improvement | 1 | 2015 | 646 | 0.320 |
Why?
|
| Hydroxyurea | 2 | 2019 | 83 | 0.300 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 409 | 0.300 |
Why?
|
| Africa | 2 | 2019 | 133 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2371 | 0.290 |
Why?
|
| Alleles | 2 | 2024 | 1615 | 0.290 |
Why?
|
| Female | 15 | 2024 | 66704 | 0.280 |
Why?
|
| Globins | 1 | 2007 | 35 | 0.280 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2007 | 12 | 0.280 |
Why?
|
| Thrombasthenia | 1 | 2007 | 2 | 0.280 |
Why?
|
| GATA1 Transcription Factor | 1 | 2007 | 9 | 0.270 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 28 | 0.270 |
Why?
|
| Anemia, Aplastic | 1 | 2007 | 57 | 0.260 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2007 | 64 | 0.260 |
Why?
|
| Hemoglobins | 2 | 2019 | 312 | 0.250 |
Why?
|
| Africa South of the Sahara | 2 | 2022 | 115 | 0.240 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 251 | 0.230 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2024 | 21 | 0.220 |
Why?
|
| Blood Platelets | 1 | 2007 | 325 | 0.220 |
Why?
|
| Infant | 5 | 2024 | 12609 | 0.220 |
Why?
|
| Morphine | 1 | 2023 | 83 | 0.210 |
Why?
|
| Immunoglobulin M | 1 | 2024 | 212 | 0.210 |
Why?
|
| Life Expectancy | 1 | 2023 | 53 | 0.210 |
Why?
|
| Hemorrhage | 1 | 2007 | 469 | 0.210 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 552 | 0.200 |
Why?
|
| Analgesics | 1 | 2023 | 127 | 0.200 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.200 |
Why?
|
| Mutation, Missense | 1 | 2007 | 879 | 0.190 |
Why?
|
| Acute Chest Syndrome | 1 | 2021 | 10 | 0.190 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2021 | 28 | 0.190 |
Why?
|
| Pneumococcal Infections | 1 | 2024 | 275 | 0.190 |
Why?
|
| Adolescent | 5 | 2024 | 19414 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 1026 | 0.180 |
Why?
|
| Neoplasms | 1 | 2015 | 2794 | 0.180 |
Why?
|
| Consensus | 1 | 2024 | 645 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2007 | 859 | 0.170 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2055 | 0.170 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 248 | 0.160 |
Why?
|
| Male | 9 | 2024 | 61443 | 0.160 |
Why?
|
| Benzaldehydes | 1 | 2019 | 11 | 0.160 |
Why?
|
| Antisickling Agents | 1 | 2019 | 18 | 0.160 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 479 | 0.160 |
Why?
|
| Cytokines | 1 | 2025 | 1293 | 0.160 |
Why?
|
| Pyrazines | 1 | 2019 | 72 | 0.150 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 174 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1027 | 0.140 |
Why?
|
| Endemic Diseases | 1 | 2017 | 57 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2019 | 306 | 0.130 |
Why?
|
| Mothers | 1 | 2019 | 356 | 0.130 |
Why?
|
| Liberia | 1 | 2016 | 8 | 0.130 |
Why?
|
| Isoelectric Focusing | 1 | 2016 | 24 | 0.130 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 14 | 0.120 |
Why?
|
| Young Adult | 3 | 2024 | 9056 | 0.120 |
Why?
|
| Host-Parasite Interactions | 1 | 2015 | 72 | 0.120 |
Why?
|
| Hematologic Tests | 1 | 2015 | 35 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2007 | 3047 | 0.120 |
Why?
|
| Biological Transport | 1 | 2015 | 355 | 0.120 |
Why?
|
| Solubility | 1 | 2015 | 139 | 0.120 |
Why?
|
| Erythrocytes | 1 | 2015 | 221 | 0.120 |
Why?
|
| Water | 1 | 2015 | 186 | 0.110 |
Why?
|
| Macaca mulatta | 1 | 2015 | 489 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 343 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 2878 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2023 | 16338 | 0.100 |
Why?
|
| Incidence | 2 | 2022 | 3131 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1265 | 0.100 |
Why?
|
| Quality of Life | 1 | 2022 | 1906 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2015 | 312 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 759 | 0.100 |
Why?
|
| Global Health | 1 | 2017 | 570 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2016 | 1395 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1320 | 0.090 |
Why?
|
| Hemolysis | 2 | 2023 | 111 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 3424 | 0.080 |
Why?
|
| Pregnancy | 1 | 2021 | 7221 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2015 | 721 | 0.080 |
Why?
|
| United States | 1 | 2023 | 10884 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2007 | 13 | 0.070 |
Why?
|
| Cholecystitis | 1 | 2007 | 20 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 105 | 0.070 |
Why?
|
| Cholecystectomy | 1 | 2007 | 58 | 0.070 |
Why?
|
| Antigens, CD20 | 1 | 2007 | 37 | 0.070 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2007 | 19 | 0.070 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2007 | 21 | 0.070 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 36 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 60 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2007 | 102 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4417 | 0.060 |
Why?
|
| Cytoplasmic Granules | 1 | 2007 | 47 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2007 | 104 | 0.060 |
Why?
|
| Prednisone | 1 | 2007 | 278 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2007 | 145 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2007 | 357 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2015 | 4821 | 0.060 |
Why?
|
| Rituximab | 1 | 2007 | 152 | 0.060 |
Why?
|
| Chromosomes, Human, X | 1 | 2007 | 158 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 398 | 0.060 |
Why?
|
| Time Factors | 1 | 2015 | 6301 | 0.060 |
Why?
|
| Heterozygote | 1 | 2007 | 672 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2007 | 306 | 0.060 |
Why?
|
| beta-Globins | 1 | 2024 | 6 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2015 | 6123 | 0.060 |
Why?
|
| Immunoassay | 1 | 2025 | 131 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1095 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 1119 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 532 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2007 | 433 | 0.050 |
Why?
|
| Failure to Thrive | 1 | 2024 | 90 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2025 | 402 | 0.050 |
Why?
|
| Recurrence | 1 | 2007 | 1390 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12272 | 0.050 |
Why?
|
| Pedigree | 1 | 2007 | 1610 | 0.050 |
Why?
|
| Point Mutation | 1 | 2024 | 351 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2007 | 671 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 125 | 0.050 |
Why?
|
| Nigeria | 1 | 2022 | 79 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 223 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 500 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2022 | 440 | 0.040 |
Why?
|
| Polymerization | 1 | 2019 | 13 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 1042 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 65 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2022 | 535 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1893 | 0.040 |
Why?
|
| Mice | 1 | 2015 | 17740 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 5169 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1158 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1685 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1605 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 1833 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 34304 | 0.030 |
Why?
|
| Adult | 2 | 2023 | 29460 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 3105 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 26676 | 0.010 |
Why?
|